MarketPulse
Q

$QURE

66 articles found
1 positive
65 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

uniQure Stock Drops 49% Following FDA Rejection of AMT-130 Accelerated Approval

uniQure stock plummeted 49% after FDA rejected accelerated approval for gene therapy AMT-130, triggering a class action lawsuit alleging securities fraud.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

uniQure Investors Face April Deadline in Securities Class Action Over FDA Disclosure Claims

Securities lawsuit against uniQure alleges misleading FDA disclosure statements about gene therapy candidate AMT-130. Stock fell 49% after November FDA feedback; investors must file claims by April 13, 2026.
QUREclass action lawsuitshareholder fraud
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

uniQure Investors Face April Deadline in Securities Litigation Over FDA Disclosure Claims

UniQure faces class action lawsuit over alleged FDA disclosure misrepresentations. Investors have until April 13, 2026 deadline to join litigation.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kessler Topaz Meltzer & Check, Llp

Securities Litigation Filed Against uniQure Over Gene Therapy Trial Misstatements

Law firm sues uniQure for allegedly misrepresenting gene therapy trial status and FDA approval timeline, causing stock to surge 250% then fall 49% after FDA reversal.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

QURE Investors Face April Deadline in Securities Class Action Over AMT-130 Claims

uniQure faces securities lawsuit alleging misleading statements about AMT-130's FDA pathway. Stock dropped 49% after FDA reversed stance. Investors have April deadline for lead plaintiff claims.
QUREsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Class Action Lawsuit Filed Against uniQure Over FDA Approval Disclosures

Rosen Law Firm sued uniQure for allegedly misleading investors about FDA approval timelines and regulatory study status between September-October 2025.
QUREsecurities fraudclass action lawsuit